Cargando…

Targeting Yes1 Associated Transcriptional Regulator Inhibits Hepatocellular Carcinoma Progression and Improves Sensitivity to Sorafenib: An in vitro and in vivo Study

PURPOSE: The aim of this study was to investigate the role of Yes1 associated transcriptional regulator (YAP1) in the pathology of hepatocellular carcinoma (HCC) and its potential as a therapeutic target. METHODS: YAP1 expression in HCC and adjacent tissues was determined via immunohistochemistry; i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Liwen, Zheng, Jiaping, Luo, Jun, Zhang, Zhewei, Shao, Guoliang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7605682/ https://www.ncbi.nlm.nih.gov/pubmed/33149619 http://dx.doi.org/10.2147/OTT.S249412

Ejemplares similares

Tumor Treating Fields (TTFields) Concomitant with Sorafenib Inhibit Hepatocellular Carcinoma In Vitro and In Vivo
por: Davidi, Shiri, et al.
Publicado: (2022)

Atorvastatin potentiates the chemosensitivity of human liver cancer cells to cisplatin via downregulating YAP1
por: Guo, Liwen, et al.
Publicado: (2021)

TEA Domain Transcription Factor 1 Inhibits Ferroptosis and Sorafenib Sensitivity of Hepatocellular Carcinoma Cells
por: Li, Hongmin, et al.
Publicado: (2023)

Evaluation of the Benefits of TACE Combined with Sorafenib for Hepatocellular Carcinoma Based on Untreatable TACE (unTACEable) Progression
por: Zou, Xinhua, et al.
Publicado: (2021)

BCRP/ABCG2 Inhibition Sensitizes Hepatocellular Carcinoma Cells to Sorafenib
por: Huang, Wei-Chien, et al.
Publicado: (2013)

Radioactive (125)I Seed Inhibits Cell Migration and Invasion and Promotes Apoptosis by Inactivating the VEGFR2 Signaling Pathway in Cholangiocarcinoma
por: Luo, Jun, et al.
Publicado: (2023)

Liver X Receptor Agonism Sensitizes a Subset of Hepatocellular Carcinoma to Sorafenib by Dual-Inhibiting MET and EGFR
por: Shao, Weiqing, et al.
Publicado: (2019)

Inhibition of neddylation modification by MLN4924 sensitizes hepatocellular carcinoma cells to sorafenib
por: Yang, Zelong, et al.
Publicado: (2019)

Camptothecin improves sorafenib sensitivity by inhibiting Nrf2‑ARE pathway in hepatocellular carcinoma
por: Sun, Liwei, et al.
Publicado: (2023)

Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro
por: Qu, Zhen, et al.
Publicado: (2016)

Effects of Sorafenib and Quercetin Alone or in Combination in Treating Hepatocellular Carcinoma: In Vitro and In Vivo Approaches
por: Abdu, Suzan, et al.
Publicado: (2022)

Simultaneous treatment with sorafenib and glucose restriction inhibits hepatocellular carcinoma in vitro and in vivo by impairing SIAH1-mediated mitophagy
por: Zhou, Jing, et al.
Publicado: (2022)

MicroRNA-339 inhibits human hepatocellular carcinoma proliferation and invasion via targeting ZNF689
por: Zeng, Hui, et al.
Publicado: (2019)

Treatment efficacy and safety of regorafenib plus drug-eluting beads-transarterial chemoembolization versus regorafenib monotherapy in colorectal cancer liver metastasis patients who fail standard treatment regimens
por: Cao, Fei, et al.
Publicado: (2021)

Therapeutic Effects of Crocin Alone or in Combination with Sorafenib against Hepatocellular Carcinoma: In Vivo & In Vitro Insights
por: Abdu, Suzan, et al.
Publicado: (2022)

YAP1 overexpression is associated with poor prognosis of breast cancer patients and induces breast cancer cell growth by inhibiting PTEN
por: Guo, Liwen, et al.
Publicado: (2019)

Sorafenib modulates the radio sensitivity of hepatocellular carcinoma cells in vitro in a schedule-dependent manner
por: Li, Qiaoqiao, et al.
Publicado: (2012)

Potential Treatment Strategies for Hepatocellular Carcinoma Cell Sensitization to Sorafenib
por: Jiang, Zhonghao, et al.
Publicado: (2023)

Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models
por: You, Abin, et al.
Publicado: (2016)

Inhibition of stress proteins TRIB3 and STC2 potentiates sorafenib sensitivity in hepatocellular carcinoma
por: Zhou, Sheng, et al.
Publicado: (2023)

Study of RNA Interference Targeting NET-1 Combination with Sorafenib for Hepatocellular Carcinoma Therapy In Vitro and In Vivo
por: He, Song, et al.
Publicado: (2013)

Kaempferol-Mediated Sensitization Enhances Chemotherapeutic Efficacy of Sorafenib Against Hepatocellular Carcinoma: An In Silico and In Vitro Approach
por: Nair, Bhagyalakshmi, et al.
Publicado: (2020)

lncRNA PCAT6 facilitates cell proliferation and invasion via regulating the miR-326/hnRNPA2B1 axis in liver cancer
por: Luo, Jun, et al.
Publicado: (2021)

Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib
por: El Dika, Imane, et al.
Publicado: (2020)

YES, a novel therapeutic target in hepatocellular carcinoma
por: Lapouge, Marjorie, et al.
Publicado: (2022)

AG-1024 Sensitizes Sorafenib-Resistant Hepatocellular Carcinoma Cells to Sorafenib via Enhancing G1/S Arrest
por: Zhou, Wei, et al.
Publicado: (2021)

Silencing activating transcription factor 2 promotes the anticancer activity of sorafenib in hepatocellular carcinoma cells
por: Luo, Lifang, et al.
Publicado: (2018)

Transcription factor glucocorticoid modulatory element-binding protein 1 promotes hepatocellular carcinoma progression by activating Yes-associate protein 1
por: Chen, Cheng, et al.
Publicado: (2023)

Chemical and genetic inhibition of STAT3 sensitizes hepatocellular carcinoma cells to sorafenib induced cell death
por: Xie, Linna, et al.
Publicado: (2018)

MicroRNA-375 Targets ATG14 to Inhibit Autophagy and Sensitize Hepatocellular Carcinoma Cells to Sorafenib
por: Yang, Shuo, et al.
Publicado: (2020)

Protein Kinase B Inactivation Is Associated with Magnolol-Enhanced Therapeutic Efficacy of Sorafenib in Hepatocellular Carcinoma In Vitro and In Vivo
por: Chen, Jiann-Hwa, et al.
Publicado: (2019)

Transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma
por: SHAO, WENBO, et al.
Publicado: (2014)

An N(6)-methyladenosine-associated lncRNA signature for predicting clinical outcome and therapeutic responses in hepatocellular carcinoma
por: Song, Danjun, et al.
Publicado: (2022)

Chloroquine inhibits hepatocellular carcinoma cell growth in vitro and in vivo
por: HU, TAO, et al.
Publicado: (2016)

Knockdown of AKR1C3 Promoted Sorafenib Sensitivity Through Inhibiting the Phosphorylation of AKT in Hepatocellular Carcinoma
por: Zheng, Jia, et al.
Publicado: (2022)

Inactivation of Transcriptional Repressor Capicua Confers Sorafenib Resistance in Human Hepatocellular Carcinoma
por: Hashiba, Tomomi, et al.
Publicado: (2020)

FTY720 (Fingolimod) sensitizes hepatocellular carcinoma cells to sorafenib-mediated cytotoxicity
por: Ahmed, Dilruba, et al.
Publicado: (2015)

Oridonin Sensitizes Hepatocellular Carcinoma to the Anticancer Effect of Sorafenib by Targeting the Akt Pathway
por: Li, Xuguang, et al.
Publicado: (2020)

The kynurenine derivative 3-HAA sensitizes hepatocellular carcinoma to sorafenib by upregulating phosphatases
por: Gan, Guifang, et al.
Publicado: (2021)

Development of an Aerobic Glycolysis Index for Predicting the Sorafenib Sensitivity and Prognosis of Hepatocellular Carcinoma
por: Pan, Yu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rlhjalr0jjo3s9crnt0ou5kqhg